IP Library Granted Patent US 9,295,781
Granted Patent B2
US 9,295,781 · App. 13/718,226 · Granted Mar 29, 2016

Borosilicate glass syringe with cone coating that increases surface roughness

Inventors: Friedrich Siebers (Nierstein, DE); Inka Henze (Nieder-Olm, DE); Juergen Thuerk (St. Gallen, CH)
Assignee: SCHOTT AG
A61M5/31A61M5/3129A61M5/3134A61M5/346Y10T428/139Y10T428/1393
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,295,781
App. No.
13/718,226
Granted
Mar 29, 2016
Kind
B2
Abstract

A syringe made of borosilicate glass and having a cone for fastening or mounting of transfer adapters and needles is provided. The cone includes a coating that increases roughness. The coating has structure-forming particles are embedded in a glass matrix and is free of Pb, Cd, Hg and Cr VI .

Claims (24)

1. A syringe comprising:

a cylinder for accommodating a liquid; and

a cone comprising borosilicate glass having a thermal expansion in the range from 20 to 300° C. of less than 6·10 −6 /K, wherein the cone encloses an outlet channel and includes an outside surface having a coating, and wherein the coating has an increased roughness compared to the outside surface and comprises a glass matrix with structure-forming particles embedded therein.

2. The syringe according to claim 1 , wherein the coating has a roughness of R q (rms) between 0.3 and 2 μm.

3. The syringe according to claim 1 , wherein the coating has a roughness of R q (rms) between 0.5 and 1.8 μm.

4. The syringe according to claim 1 , wherein the coating has an average layer thickness from 0.5 to 20 μm.

5. The syringe according to claim 1 , wherein the glass matrix has a viscosity of less than or equal to 10 6 dPas below 700° C.

6. The syringe according to claim 1 , wherein the structure-forming particles are ceramic or glass particles having an average particle size (d 50 ) from 0.2 to 5 μm.

7. The syringe according to claim 1 , wherein the structure-forming particles make up a proportion of between 1 and 30% by weight of the coating.

8. The syringe according to claim 1 , wherein the structure-forming particles comprise a material having a thermal expansion in the temperature range from 20 to 300° C. of less than 8·10 −6 /K.

9. The syringe according to claim 8 , wherein the glass matrix comprises a material having a thermal expansion of less than 7.5·10 −6 /K in the temperature range from 20 to 300° C.

10. The syringe according to claim 9 , wherein the glass matrix comprises a material having a thermal expansion of less than 7·10 −6 /K in the temperature range from 20 to 300° C.

11. The syringe according to claim 1 , wherein the glass matrix comprises a material having a thermal expansion of less than 7.5·10 −6 /K in the temperature range from 20 to 300° C.

12. The syringe according to claim 11 , wherein the glass matrix comprises a material having a thermal expansion of less than 7·10 −6 /K in the temperature range from 20 to 300° C.

13. The syringe according to claim 1 , wherein the glass matrix comprises 40 to 75% by weight of Bi 2 0 3 , 3 to 20% by weight of B 2 0 3 , and 10 to 30% by weight of SiO 2 .

14. The syringe according to claim 1 , wherein the glass matrix comprises 15 to 48% by weight of ZnO, 8 to 40% by weight of B 2 0 3 , and 8 to 52% by weight of SiO 2 .

15. The syringe according to claim 1 , wherein the coating is symmetrically disposed around the outside surface.

16. The syringe according to claim 15 , wherein the coating has a width of between 2 and 10 mm.

17. The syringe according to claim 1 , wherein the borosilicate glass has a thermal expansion in the range from 20° C. to 300° C. of 4.5·10 −6 /K to 5.5·10 −6 /K.

18. The syringe according to claim 1 , wherein the borosilicate glass has a thermal expansion in the range from 20° C. to 300° C. of less than 5.0·10 −6 /K.

19. The syringe according to claim 1 , wherein the syringe comprises a total of less than 100 ppm of Pb, Cd, Hg and Cr VI .

20. The syringe according to claim 1 , wherein the syringe comprises a total of less than 1000 ppm of Pb, Cd, Hg and Cr VI .

21. The syringe according to claim 1 , wherein the coating does not completely cover the cone.

22. The syringe according to claim 1 , wherein the outside surface of cone has the coating in a manner that provides coated areas and island-like subregions that are free of the coating.

Assignments (3)
NUNC PRO TUNC ASSIGNMENT Recorded Sep 21, 2023
From: SCHOTT PHARMA AG & CO. KGAA
To: SCHOTT PHARMA AG & CO. KGAA; SCHOTT PHARMA SCHWEIZ AG
Reel/Frame 064978/0962 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2022
From: SCHOTT AG
To: SCHOTT PHARMA AG & CO. KGAA
Reel/Frame 061972/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2013
From: SIEBERS, FRIEDRICH; HENZE, INKA; THUERK, JUERGEN
To: SCHOTT AG
Reel/Frame 029973/0513 →
Priority Claims (1)
DE 10 2011 089 045 · Dec 19, 2011 · national
Continuity (1)
Related Publication 20130158485A1 · Jun 20, 2013